⌘K

Home/Filings/4/0001209191-23-018501

4//SEC Filing

DiFabio Andrea 4

Accession 0001209191-23-018501

CIK 0001582313other

View on SEC.gov Company Profile

Filed

Mar 13, 8:00 PM ET

Accepted

Mar 14, 4:44 PM ET

Size

5.3 KB

Accession

0001209191-23-018501

Insider Transaction Report

Form 4

Period: 2023-03-10

Xenon Pharmaceuticals Inc.XENE

Chief Legal Officer

Transactions

Award
Stock Option (Right to Buy)
2023-03-10+45,000→ 45,000 total
Exercise: $34.18Exp: 2033-03-09→ Common Shares (45,000 underlying)

Footnotes (1)

[F1]Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Xenon Pharmaceuticals Inc.

CIK 0001582313

Entity typeother

Related Parties

1

filerCIK 0001692506

Filing Metadata

Form type: 4
Filed: Mar 13, 8:00 PM ET
Accepted: Mar 14, 4:44 PM ET
Size: 5.3 KB

View on SEC.gov